Literature DB >> 23100275

Large inter-individual variation of the pharmacodynamic effect of anticoagulant drugs on thrombin generation.

Saartje Bloemen1, H Coenraad Hemker, Raed Al Dieri.   

Abstract

Anticoagulation by a standard dosage of an inhibitor of thrombin generation presupposes predictable pharmacokinetics and pharmacodynamics of the anticoagulant. We determined the inter-individual variation of the effect on thrombin generation of a fixed concentration of direct and antithrombin-mediated inhibitors of thrombin and factor Xa. Thrombin generation was determined by calibrated automated thrombinography in platelet-poor plasma from 44 apparently healthy subjects which was spiked with fixed concentrations of otamixaban, melagatran, unfractionated heparin, dermatan sulfate and pentasaccharide. The variability of the inhibitory effect of the different anticoagulants within the population was determined using the coefficient of variation, i.e. the standard deviation expressed as a percentage of the mean. The inter-individual coefficients of variation of the endogenous thrombin potential and peak height before inhibition were 18% and 16%, respectively and became 20%-24% and 24%-43% after inhibition. The average inhibition of endogenous thrombin potential and peak height (ETP, peak) brought about by the anticoagulants was respectively: otamixaban (27%, 83%), melagatran (56%, 63%), unfractionated heparin (43%, 58%), dermatan sulfate (68%, 57%) and pentasaccharide (25%, 67%). This study demonstrates that the addition of a fixed concentration of any type of anticoagulant tested causes an inhibition that is highly variable from one individual to another. In this respect there is no difference between direct inhibitors of thrombin and factor Xa and heparin(-like) inhibitors acting on the same factors.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23100275      PMCID: PMC5490471          DOI: 10.3324/haematol.2012.073601

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  45 in total

1.  In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban.

Authors:  G T Gerotziafas; I Elalamy; F Depasse; E Perzborn; M M Samama
Journal:  J Thromb Haemost       Date:  2007-02-07       Impact factor: 5.824

Review 2.  Laboratory monitoring of anticoagulation: where do we stand?

Authors:  Armando Tripodi; Antonius van den Besselaar
Journal:  Semin Thromb Hemost       Date:  2009-03-23       Impact factor: 4.180

3.  New oral antithrombotics: a need for laboratory monitoring. For.

Authors:  P Mismetti; S Laporte
Journal:  J Thromb Haemost       Date:  2010-01-21       Impact factor: 5.824

4.  Epidemiology of coagulation factors, inhibitors and activation markers: The Third Glasgow MONICA Survey. II. Relationships to cardiovascular risk factors and prevalent cardiovascular disease.

Authors:  M Woodward; G D Lowe; A Rumley; H Tunstall-Pedoe; H Philippou; D A Lane; C E Morrison
Journal:  Br J Haematol       Date:  1997-06       Impact factor: 6.998

5.  Pharmacological characterization of a novel factor Xa inhibitor, FXV673.

Authors:  V Chu; K Brown; D Colussi; J Gao; J Bostwick; C Kasiewski; R Bentley; S Morgan; K Guertin; H W Pauls; Y Gong; A Zulli; M H Perrone; C T Dunwiddie; R J Leadley
Journal:  Thromb Res       Date:  2001-08-15       Impact factor: 3.944

Review 6.  Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism.

Authors:  Petra Mg Erkens; Martin H Prins
Journal:  Cochrane Database Syst Rev       Date:  2010-09-08

7.  The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Authors:  Jack Ansell; Jack Hirsh; Leon Poller; Henry Bussey; Alan Jacobson; Elaine Hylek
Journal:  Chest       Date:  2004-09       Impact factor: 9.410

8.  Maturation of the hemostatic system during childhood.

Authors:  M Andrew; P Vegh; M Johnston; J Bowker; F Ofosu; L Mitchell
Journal:  Blood       Date:  1992-10-15       Impact factor: 22.113

9.  Free factor Xa is on the main pathway of thrombin generation in clotting plasma.

Authors:  H C Hemker; J Choay; S Beguin
Journal:  Biochim Biophys Acta       Date:  1989-09-15

10.  Risk of stroke during long-term anticoagulant therapy in patients after myocardial infarction.

Authors:  A J Azar; P J Koudstaal; A R Wintzen; P F van Bergen; J J Jonker; J W Deckers
Journal:  Ann Neurol       Date:  1996-03       Impact factor: 10.422

View more
  11 in total

1.  A pilot study of procoagulant platelet extracellular vesicles and P-selectin increase during induction treatment in acute lymphoblastic leukaemia paediatric patients: two new biomarkers of thrombogenic risk?

Authors:  Claire Pluchart; Coralie Barbe; Gael Poitevin; Sandra Audonnet; Philippe Nguyen
Journal:  J Thromb Thrombolysis       Date:  2020-11-28       Impact factor: 2.300

2.  Periprocedural management of anticoagulation for atrial fibrillation catheter ablation in direct oral anticoagulant-treated patients.

Authors:  Anne-Céline Martin; Sarah Lessire; Isabelle Leblanc; Anne-Sophie Dincq; Ivan Philip; Isabelle Gouin-Thibault; Anne Godier
Journal:  Clin Cardiol       Date:  2018-05-10       Impact factor: 2.882

3.  Differential in vitro inhibition of thrombin generation by anticoagulant drugs in plasma from patients with cirrhosis.

Authors:  Wilma Potze; Freeha Arshad; Jelle Adelmeijer; Hans Blokzijl; Arie P van den Berg; Joost C M Meijers; Robert J Porte; Ton Lisman
Journal:  PLoS One       Date:  2014-02-04       Impact factor: 3.240

4.  Unfractionated and Low-Molecular-Weight Heparin and the Phosphodiesterase Inhibitors, IBMX and Cilostazol, Block Ex Vivo Equid Herpesvirus Type-1-Induced Platelet Activation.

Authors:  Tracy Stokol; Priscila Beatriz da Silva Serpa; Muhammad N Zahid; Marjory B Brooks
Journal:  Front Vet Sci       Date:  2016-11-17

5.  Prediction of bleeding risk in patients taking vitamin K antagonists using thrombin generation testing.

Authors:  Saartje Bloemen; Suzanne Zwaveling; Hugo Ten Cate; Arina Ten Cate-Hoek; Bas de Laat
Journal:  PLoS One       Date:  2017-05-04       Impact factor: 3.240

6.  Assessment of the analytical performances and sample stability on ST Genesia system using the STG-DrugScreen application.

Authors:  Jonathan Douxfils; Laure Morimont; Céline Bouvy; Marie de Saint-Hubert; Bérangère Devalet; Célia Devroye; Anne-Sophie Dincq; Jean-Michel Dogné; Maïté Guldenpfennig; Justine Baudar; Anne-Sophie Larock; Sarah Lessire; François Mullier
Journal:  J Thromb Haemost       Date:  2019-05-31       Impact factor: 5.824

7.  Heparins: A Shift of Paradigm.

Authors:  H Coenraad Hemker; Raed Al Dieri; Suzette Béguin
Journal:  Front Med (Lausanne)       Date:  2019-11-15

8.  New oral anticoagulants: are coagulation units still required?

Authors:  Raul Altman
Journal:  Thromb J       Date:  2014-02-03

9.  The modification of the thrombin generation test for the clinical assessment of dabigatran etexilate efficiency.

Authors:  Irina V Gribkova; Elena N Lipets; Irina G Rekhtina; Alex I Bernakevich; Dorzho B Ayusheev; Ruzanna A Ovsepyan; Fazoil I Ataullakhanov; Elena I Sinauridze
Journal:  Sci Rep       Date:  2016-07-05       Impact factor: 4.379

10.  Inhibition of thrombin generation 12 hours after intake of direct oral anticoagulants.

Authors:  Michael Metze; Christian Pfrepper; Tristan Klöter; Stephan Stöbe; Roland Siegemund; Thomas Siegemund; Elvira Edel; Ulrich Laufs; Sirak Petros
Journal:  Res Pract Thromb Haemost       Date:  2020-04-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.